In a phase 1/2 clinical study, autologous CD34+ cells genetically modified with a lentiviral vector encoding for human WAS cDNA12, 14 were re-infused to patients with severe Wiskott-Aldrich syndrome after a reduced-intensity conditioning regimen.16 This evidence concerns the gene WAS and Wiskott-Aldrich syndrome.